PKM and metabolic dysfunction-associated steatohepatitis: In contrast, Annexin A5 (ANXA5) presents a counter-regulatory mechanism by interacting with PKM2 to inhibit its phosphorylation, thus promoting the formation of metabolically active tetramers and modulating macrophage activation in NASH (166).